Online citations, reference lists, and bibliographies.
Please confirm you are human
(Sign Up for free to never see this)
← Back to Search

Advances In The Management Of Metastatic Breast Cancer: Options Beyond First-line Chemotherapy.

J. Ayoub, S. Verma, S. Verma
Published 2012 · Medicine

Save to my Library
Download PDF
Analyze on Scholarcy
Share
This article provides an overview of recent advances in chemotherapy that may be used for the treatment of patients with locally advanced or metastatic breast cancer (MBC). Key phase ii and iii trial data for eribulin mesylate, ixabepilone, and nab-paclitaxel, published since 2006, are discussed on the basis of recency, depth, and quality.Eribulin mesylate is the first monotherapy to significantly increase overall survival in patients with pretreated MBC, but nab-paclitaxel offers a novel and safer mode of delivery in comparison with standard taxanes. By contrast, the use of ixabepilone will be limited for now, until the associated neurotoxicity can be better managed. Alongside a brief overview of the other major chemotherapies currently in use, we have aimed to provide a Canadian context for how these novel agents may be integrated into clinical practice.
This paper references
10.1200/JCO.1999.17.2.485
Multicenter phase II study of capecitabine in paclitaxel-refractory metastatic breast cancer.
J. Blum (1999)
Facts and controversies in the treatment of metastatic breast cancer
C Bernard – Marty (2004)
10.1200/JCO.2008.18.5397
Significantly longer progression-free survival with nab-paclitaxel compared with docetaxel as first-line therapy for metastatic breast cancer.
W. Gradishar (2009)
10.1002/cncr.11577
Weekly vinorelbine is an effective palliative regimen after failure with anthracyclines and taxanes in metastatic breast carcinoma.
L. Zelek (2001)
Ixempra (Ixabepilone) Prescribing Information
Bristol–Myers Squibb (2010)
10.1093/annonc/mdq160
Locally recurrent or metastatic breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.
F. Cardoso (2010)
Management of the
M. Martin (2005)
10.1517/13543784.17.4.593
Ixabepilone, a novel epothilone analog in the treatment of breast cancer.
X. Pivot (2008)
10.1186/1471-2407-11-373
Single-agent pegylated liposomal doxorubicin (PLD) in the treatment of metastatic breast cancer: results of an Austrian observational trial
M. Fiegl (2011)
10.1093/OXFORDJOURNALS.ANNONC.A058873
Vinorelbine (navelbine) as a salvage treatment for advanced breast cancer.
M. Degardin (1994)
10.1016/j.critrevonc.2011.01.010
Treatment of metastatic breast cancer: state-of-the-art, subtypes and perspectives.
N. E. El Saghir (2011)
Correspondence to: Shailendra Verma, The Ottawa Hospital Cancer Centre, 501 Smyth Road
10.1177/1758834010386402
Synergistic activity of ixabepilone plus other anticancer agents: preclinical and clinical evidence
F. Lee (2011)
10.1200/JCO.2006.09.7535
Phase II clinical trial of ixabepilone (BMS-247550), an epothilone B analog, as first-line therapy in patients with metastatic breast cancer previously treated with anthracycline chemotherapy.
H. Roché (2007)
10.1200/JCO.2005.11.013
Multicenter phase II trial of ABI-007, an albumin-bound paclitaxel, in women with metastatic breast cancer.
N. Ibrahim (2005)
10.1016/j.breast.2011.06.004
Management of breast cancer with nanoparticle albumin-bound (nab)-paclitaxel combination regimens: a clinical review.
J. Chirgwin (2011)
Multicenter, phase ii study of capecitabine in paclitaxel-refractory metastatic breast carcinoma patients
Jl Blum (2001)
10.32388/s9y2ce
Medical oncology.
S. North (1971)
The Ottawa Hospital Cancer Centre
Medical Oncology
10.1093/ANNONC/MDG346
Multicenter phase II study of oral capecitabine (Xeloda(")) in patients with metastatic breast cancer relapsing after treatment with a taxane-containing therapy.
P. Reichardt (2003)
10.1093/annonc/mdq069
Optimising the dose of capecitabine in metastatic breast cancer: confused, clarified or confirmed?
C. Zielinski (2010)
10.4065/84.6.533
Treatment Options for Breast Cancer Resistant to Anthracycline and Taxane
Alvaro Moreno-Aspitia (2009)
10.1200/JCO.2006.24.18_SUPPL.12017
Preclinical efficacy evaluation of ixabepilone (BMS-247550) in combination with cetuximab or capecitabine in human colon and lung carcinoma xenografts.
F. Lee (2006)
10.4137/BCBCR.S5857
Safety and Efficacy of nab-Paclitaxel in the Treatment of Patients with Breast Cancer
P. Vishnu (2011)
10.1007/s10549-009-0658-9
A phase II trial of trastuzumab plus weekly ixabepilone and carboplatin in patients with HER2-positive metastatic breast cancer: an Eastern Cooperative Oncology Group Trial
S. Moulder (2009)
10.1093/JNCI/83.4.288
Studies with RP 56976 (taxotere): a semisynthetic analogue of taxol.
I. Ringel (1991)
10.1093/ANNONC/MDI904
Chemotherapy for metastatic breast cancer.
S. Barni (2005)
10.1200/JCO.2002.09.002
Superior survival with capecitabine plus docetaxel combination therapy in anthracycline-pretreated patients with advanced breast cancer: phase III trial results.
J. O'Shaughnessy (2002)
Navelbine (Vinorelbine Tartrate) Injection [product monograph]
Pierre Fabre (2005)
10.1517/13543784.17.3.423
Ixabepilone for the treatment of solid tumors: a review of clinical data.
N. Denduluri (2008)
10.1517/14656560902834961
Therapeutic options for metastatic breast cancer.
P. Morris (2009)
10.1016/S0025-6196(11)60585-5
Treatment options for breast cancer resistant to anthracycline and taxane.
A. Moreno-Aspitia (2009)
10.1200/JCO.2005.02.167
Safety and efficacy of two different doses of capecitabine in the treatment of advanced breast cancer in older women.
E. Bajetta (2005)
10.1200/JCO.2007.10.8407
Evaluation of tumor response, disease control, progression-free survival, and time to progression as potential surrogate end points in metastatic breast cancer.
T. Burzykowski (2008)
Phase ii trial of weekly nab-paclitaxel in combination with bevacizumab as first-line treatment in metastatic breast cancer [abstract 1075
MA Danso (2012)
BMS-247550: a novel epothilone analog with a mode of action similar to paclitaxel but possessing superior antitumor efficacy.
F. Lee (2001)
Triple negative breast cancer: epidemiology and management options
S Dawood (2010)
10.1007/s10549-010-0901-4
Analysis of overall survival from a phase III study of ixabepilone plus capecitabine versus capecitabine in patients with MBC resistant to anthracyclines and taxanes
G. Hortobágyi (2010)
10.1093/annonc/mdn661
Phase II trial of weekly nab (nanoparticle albumin-bound)-paclitaxel (nab-paclitaxel) (Abraxane) in combination with gemcitabine in patients with metastatic breast cancer (N0531).
V. Roy (2009)
10.1093/annonc/mdr382
Cytotoxic drugs for patients with breast cancer in the era of targeted treatment: back to the future?
J. T. Ribeiro (2012)
Invasive breast cancer: clinical practice guidelines in oncology
Rw Carlson (2011)
Ixempra (Ixabepilone) Prescribing Information
Myers Bristol (2010)
therapy for women with advanced breast cancer (bc)
(2009)
10.1634/theoncologist.2010-0278
In the end what matters most? A review of clinical endpoints in advanced breast cancer.
S. Verma (2011)
10.1093/ANNONC/MDM229
Role of liposomal anthracyclines in breast cancer.
V. Lorusso (2007)
Clinical and pharmacokinetic study of ixabepilone (ixa) plus epirubicin (epi) as
L Gianni
10.5694/j.1326-5377.1970.tb63183.x
THE MANAGEMENT OF ADVANCED BREAST CANCER
M. Baum (1980)
10.7164/ANTIBIOTICS.49.560
Epothilons A and B: antifungal and cytotoxic compounds from Sorangium cellulosum (Myxobacteria). Production, physico-chemical and biological properties.
K. Gerth (1996)
10.1200/JCO.2008.26.15_SUPPL.1075
Phase II trial of weekly nab-paclitaxel in combination with bevacizumab as first-line treatment in metastatic breast cancer
M. Danso (2008)
10.1038/sj.bjc.6600261
Randomised, phase II trial comparing oral capecitabine (Xeloda®) with paclitaxel in patients with metastatic/advanced breast cancer pretreated with anthracyclines
D. Talbot (2002)
10.1073/pnas.191367098
Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications
T. Sørlie (2001)
10.1200/JCO.2007.25.18_SUPPL.1053
Phase II trial of nab-paclitaxel (nanoparticle albumin-bound paclitaxel (ABX)) + capecitabine (XEL) in first-line treatment of metastatic breast cancer (MBC)
B. Somer (2007)
10.2147/OTT.S13836
Nab-paclitaxel for the treatment of breast cancer: efficacy, safety, and approval
Y. Yamamoto (2011)
10.1200/JCO.2005.04.937
Phase III trial of nanoparticle albumin-bound paclitaxel compared with polyethylated castor oil-based paclitaxel in women with breast cancer.
W. Gradishar (2005)
Following publication in Current Oncology, the full text of each article is available immediately and archived in PubMed Central (PMC)
Copyright
Global cancer rates could increase by 50% to 15 million by 2020 [press release]. Geneva , Switzerland: who; 2003. [Available online at: http:// www.who.int/mediacentre/news/releases
(2003)
Triple negative breast cancer: epidemiology and management options. Drugs 2010;70:2247–58
S. Dawood (2010)
10.1200/JCO.2010.33.9101
Capecitabine versus classical cyclophosphamide, methotrexate, and fluorouracil as first-line chemotherapy for advanced breast cancer.
M. Stockler (2011)
10.1038/277665a0
Promotion of microtubule assembly in vitro by taxol
PETER B. Schiff (1979)
10.1093/ANNONC/MDP261
Third consensus on medical treatment of metastatic breast cancer
D. Berthold (2006)
10.1634/THEONCOLOGIST.9-6-617
Facts and controversies in systemic treatment of metastatic breast cancer.
C. Bernard-Marty (2004)
10.1200/JCO.2007.12.6557
Ixabepilone plus capecitabine for metastatic breast cancer progressing after anthracycline and taxane treatment.
E. Thomas (2007)
10.1093/jnci/djq029
International Guidelines for Management of Metastatic Breast Cancer: Can Metastatic Breast Cancer Be Cured?
O. Pagani (2010)
10.1200/JCO.2004.00.6148
Phase I and pharmacokinetics trial of ABI-007, a novel nanoparticle formulation of paclitaxel in patients with advanced nonhematologic malignancies.
D. Nyman (2005)
10.1007/s10549-007-9550-7
Impact of chemotherapy beyond the first line in patients with metastatic breast cancer
A. Dufresne (2007)
10.1200/JCO.1994.12.10.2094
Vinorelbine is an active antiproliferative agent in pretreated advanced breast cancer patients: a phase II study.
G. Gasparini (1994)
10.1016/S0140-6736(11)60070-6
Eribulin monotherapy versus treatment of physician's choice in patients with metastatic breast cancer (EMBRACE): a phase 3 open-label randomised study
J. Cortés (2011)
10.1200/JCO.2009.24.4244
Randomized phase III trial of ixabepilone plus capecitabine versus capecitabine in patients with metastatic breast cancer previously treated with an anthracycline and a taxane.
J. Sparano (2010)
10.1200/JCO.2006.09.3849
Efficacy and safety of ixabepilone (BMS-247550) in a phase II study of patients with advanced breast cancer resistant to an anthracycline, a taxane, and capecitabine.
E. Perez (2007)
10.1023/A:1012281104865
Randomized, open-label, phase II trial of oral capecitabine (Xeloda) vs. a reference arm of intravenous CMF (cyclophosphamide, methotrexate and 5-fluorouracil) as first-line therapy for advanced/metastatic breast cancer.
J. Oshaughnessy (2001)
10.1200/JCO.2008.17.7618
Phase II study of eribulin mesylate, a halichondrin B analog, in patients with metastatic breast cancer previously treated with an anthracycline and a taxane.
L. Vahdat (2009)
Gemcitabine plus paclitaxel versus paclitaxel monotherapy in patients with Current OnCOlOgy—VOlume 19
Ks Albain (2012)
Navelbine (Vinorelbine Tartrate) Injection [product monograph
Pierre Fabre Pharma Canada (2005)
10.2146/ajhp070628
Ixabepilone: a novel microtubule-stabilizing agent for the treatment of metastatic breast cancer.
S. Goodin (2008)
10.1016/J.EJCA.2004.08.021
Molecular portraits of breast cancer: tumour subtypes as distinct disease entities.
T. Sørlie (2004)
10.1097/00001813-199902000-00003
Phase II study of gemcitabine as first-line chemotherapy in patients with advanced or metastatic breast cancer.
K. Possinger (1999)
10.1016/S0305-7372(03)00139-7
Platinum-based chemotherapy in metastatic breast cancer: current status.
M. Decatris (2004)
10.1200/JCO.2006.08.9102
Phase II clinical trial of ixabepilone (BMS-247550), an epothilone B analog, in patients with taxane-resistant metastatic breast cancer.
E. Thomas (2007)
10.1053/j.seminoncol.2008.02.008
Emerging agents in the treatment of anthracycline- and taxane-refractory metastatic breast cancer.
W. Dean-Colomb (2008)
10.1159/000048240
Gemcitabine as First-Line Therapy in Patients with Metastatic Breast Cancer: A Phase II Trial
M. Blackstein (2002)
10.2147/CMAR.S10570
Ixabepilone development across the breast cancer continuum: a paradigm shift
N. Ibrahim (2010)
10.1186/bcr2573
Chemotherapy resistance in metastatic breast cancer: the evolving role of ixabepilone
E. Rivera (2010)
on behalf of the esmo Guidelines Working Group. Locally recurrent or metastatic breast cancer: esmo clinical practice guidelines for diagnosis, treatment and follow-up
F Cardoso (2010)
10.1200/JCO.2003.08.013
Phase III trial of doxorubicin, paclitaxel, and the combination of doxorubicin and paclitaxel as front-line chemotherapy for metastatic breast cancer: an intergroup trial (E1193).
G. Sledge (2003)
10.1200/JCO.2005.10.024
Phase II clinical trial of ixabepilone (BMS-247550), an epothilone B analog, in metastatic and locally advanced breast cancer.
J. Low (2005)
10.1016/S1470-2045(07)70041-4
Gemcitabine plus vinorelbine versus vinorelbine monotherapy in patients with metastatic breast cancer previously treated with anthracyclines and taxanes: final results of the phase III Spanish Breast Cancer Research Group (GEICAM) trial.
M. Martín (2007)
10.1200/JCO.2008.26.15_SUPPL.1118
Single-agent nab-paclitaxel given weekly (3/4) as first-line therapy for metastatic breast cancer (an International Oncology Network study, #I-04-012)
B. Mirtsching (2008)
10.3816/CBC.2008.n.026
Phase I/II study of ixabepilone plus capecitabine in anthracycline-pretreated/resistant and taxane-resistant metastatic breast cancer.
C. Bunnell (2008)
Phase II trial of weekly nab ( nanoparticle albumin-bound )-paclitaxel ( nab-paclitaxel ) ( Abraxane ) in combination with gemcitabine in patients with metastatic breast cancer ( N 0531 )
V. Roy (2009)
Available online at: http://www.asco. org/ascov2/Meetings/Abstracts?&vmview=abst_detail_view &confID=55&abstractID=35599
(2008)
J Clin Oncol
(2005)
10.1007/s11912-010-0145-9
The Place for Eribulin in the Treatment of Metastatic Breast Cancer
W. Gradishar (2011)
Epothilones, a new class of microtubule-stabilizing agents with a taxol-like mechanism of action.
D. M. Bollag (1995)
10.1200/JCO.2003.11.071
Are anthracycline-taxane regimens the new standard of care in the treatment of metastatic breast cancer?
V. Valero (2003)
E-mail: sverma@ottawahospital.on.ca * Hematology–Oncology Service
Are anthracycline-taxane regimens the new standard of care in the treatment of breast cancer?
V Valero (2003)
Following publication in Current Oncology, the full text of each article is available immediately and archived in PubMed Central (PMC). metastatic breast cancer and prior anthracycline treatment
Copyright (2008)
10.1200/JCO.2007.11.6699
Randomized phase III trial of weekly compared with every-3-weeks paclitaxel for metastatic breast cancer, with trastuzumab for all HER-2 overexpressors and random assignment to trastuzumab or not in HER-2 nonoverexpressors: final results of Cancer and Leukemia Group B protocol 9840.
A. Seidman (2008)
10.1016/J.EJCA.2003.11.007
Multicentre, phase II study evaluating capecitabine monotherapy in patients with anthracycline- and taxane-pretreated metastatic breast cancer.
P. Fumoleau (2004)
10.1200/JCO.2009.25.8467
Phase II study of the halichondrin B analog eribulin mesylate in patients with locally advanced or metastatic breast cancer previously treated with an anthracycline, a taxane, and capecitabine.
J. Cortés (2010)
Phase ii trial of nab-paclitaxel (nanoparticle albumin-bound paclitaxel: abx) + capecitabine (xel) in first line treatment of metastatic breast cancer (mbc) [abstract 1053]
Bg Somer (2007)
10.1126/SCIENCE.1099190
The Binding Mode of Epothilone A on α,ß-Tubulin by Electron Crystallography
J. Nettles (2004)
10.1002/1097-0142(20011001)92:7<1759::AID-CNCR1691>3.0.CO;2-A
Multicenter, Phase II study of capecitabine in taxane‐pretreated metastatic breast carcinoma patients
J. Blum (2001)
10.1093/annonc/mdr024
Pegylated liposomal doxorubicin in combination with cyclophosphamide and trastuzumab in HER2-positive metastatic breast cancer patients: efficacy and cardiac safety from the GEICAM/2004-05 study.
M. Martín (2011)
Clinical and pharmacokinetic study of ixabepilone (ixa) plus epirubicin (epi) as AYOUB et al
L Gianni (2012)
10.1158/1535-7163.MCT-04-0345
The primary antimitotic mechanism of action of the synthetic halichondrin E7389 is suppression of microtubule growth
M. Jordan (2005)
10.3816/CBC.2007.n.049
Phase II study of weekly albumin-bound paclitaxel for patients with metastatic breast cancer heavily pretreated with taxanes.
Joanne L. Blum (2007)
Current OnCOlOgy—VOlume
(2012)
Castiglione M on behalf of the esmo Guidelines Working Group. Locally recurrent or metastatic breast cancer: esmo clinical practice guidelines for diagnosis, treatment and follow-up
F Cardoso (2010)



This paper is referenced by
10.7150/jca.8748
Eribulin Mesylate in Pretreated Breast Cancer Patients: A Multicenter Retrospective Observational Study
T. Gamucci (2014)
10.1007/s10549-013-2742-4
Phase II randomized trial of weekly and every-3-week ixabepilone in metastatic breast cancer patients
J. Smith (2013)
10.1007/s40259-013-0038-1
Evolving Approaches to Metastatic Breast Cancer Patients Pre-treated with Anthracycline and Taxane
S. Saji (2013)
The Effects of Anthracycline/Taxane Adjuvant Chemotherapy and Resistance Exercise on Body Composition, Muscle Strength, Quality of Life and Fatigue in Breast Cancer Survivors
R. Lal (2016)
Breast cancer metastatic dormancy and emergence, a role for adjuvant statin therapy
Colin H. Beckwitt (2018)
10.1007/s12282-017-0798-4
Phase I dose-finding study of eribulin and capecitabine for metastatic breast cancer: JBCRG-18 cape study
M. Hattori (2017)
Investigating the effects of CSF-1R and PI3Kdelta inhibition on a breast cancer bone metastasis model
Carolina Salazar Arcila (2013)
O CANCRO DA MAMA METASTIZADO É CURÁVEL? A PROPÓSITO DE UM CASO CLÍNICO
Vânia Alexandra (2013)
10.4103/2278-960X.112571
Eribulin mesylate: A new therapeutic option for metastatic breast cancer
S. Aditya (2013)
10.1517/14656566.2016.1154537
Etirinotecan pegol for the treatment of breast cancer
E. López-Miranda (2016)
10.2217/fon-2019-0180
ATTAIN: Phase III study of etirinotecan pegol versus treatment of physician's choice in patients with metastatic breast cancer and brain metastases.
D. Tripathy (2019)
10.1016/j.cmet.2019.07.015
Podoplanin-Expressing Macrophages Promote Lymphangiogenesis and Lymphoinvasion in Breast Cancer.
Paweł Bieniasz-Krzywiec (2019)
Individualizing treatment to optimize survival outcomes in breast cancer.
E. Perez (2013)
Why Are Canada ’ s OECD Numbers Different From Those in CIHI and Statistics Canada Reports ?
(2013)
10.1155/2020/9645294
Chemotherapy Options beyond the First Line in HER-Negative Metastatic Breast Cancer
V. Lorusso (2020)
10.1186/s13020-018-0222-9
An innovative anti-cancer Chinese herbal formula exhibited multi-targeted efficacies in metastatic breast cancer mouse model
G. Yue (2018)
10.1007/s11095-019-2684-6
Dual-Targeted Delivery of Nanoparticles Encapsulating Paclitaxel and Everolimus: a Novel Strategy to Overcome Breast Cancer Receptor Heterogeneity
Loujin Houdaihed (2020)
Semantic Scholar Logo Some data provided by SemanticScholar